Tempest Therapeutics adds Drake Richey, John Yee to board

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc.

TPST

0.00
  • Tempest Therapeutics appointed Drake Richey, president of Bush & Company, and John Yee, MD, MPH, SVP medical affairs at Apnimed, to its board.
  • Richey previously led Life Check, worked as a portfolio manager at Wells Fargo, and held a director role at Fitch Ratings.
  • Yee previously served as CMO at Sobi North America, held senior medical affairs roles at Flexion and Vertex, and worked at AstraZeneca.
  • Appointments take effect June 4, 2026; both directors join as independents.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606041637PRIMZONEFULLFEED9732191) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.